Loading…
Rapport Therapeutics, Inc. is projected to rise to $53.45 by 2027, a +28% move from its current price of $41.75. RAPP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $40.65 | $41.76 | $42.90 | +0.02% |
| Jul 15 | $40.20 | $41.77 | $43.39 | +0.04% |
| Jul 16 | $39.87 | $41.77 | $43.77 | +0.06% |
| Jul 17 | $39.59 | $41.78 | $44.10 | +0.08% |
| Jul 18 | $39.34 | $41.79 | $44.39 | +0.10% |
| Jul 19 | $39.12 | $41.80 | $44.65 | +0.11% |
| Jul 20 | $38.93 | $41.81 | $44.90 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $38.93 | $41.81 | $44.90 | +0.13% |
| Week 2 | $37.84 | $41.86 | $46.31 | +0.27% |
| Week 3 | $37.04 | $41.92 | $47.43 | +0.40% |
| Week 4 | $36.39 | $41.97 | $48.42 | +0.54% |
| Week 5 | $35.83 | $42.03 | $49.30 | +0.67% |
| Week 6 | $35.33 | $42.09 | $50.13 | +0.80% |
| Week 7 | $34.89 | $42.14 | $50.90 | +0.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is RAP-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders.
The company also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. Rapport Therapeutics, Inc. was formerly known as Precision Neuroscience NewCo, Inc.
and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Rapport Therapeutics, Inc. trades under the symbol RAPP in the Healthcare category. The current price is $40.39 and the market capitalization stands at $1.93B, with a rank of 1974.
The near-term outlook shows a 2026 forecast with an average price of $40.39, a min of $25.55 and a max of $54.42, and a neutral sentiment. The 30-day price action ranges from $33.71 to $48.40, underscoring modest near-term volatility.
A major floor 36.6% below — a decisive break under it would weaken the trend.
The nearest floor, 16.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.7% away) — a breakout level to watch.
A major ceiling 11.9% above — clearing it would confirm fresh momentum.
Key RAPP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RAPP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.82 | Buy | $41.17 | Buy |
| MA 10 | $40.46 | Buy | $40.47 | Buy |
| MA 20 | $39.26 | Buy | $39.55 | Buy |
| MA 50 | $37.77 | Buy | $37.73 | Buy |
| MA 100 | $34.57 | Buy | $35.16 | Buy |
| MA 200 | $31.06 | Buy | $31.08 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.73 | Neutral |
| Stoch RSI (14) | 73.84 | Neutral |
| CCI (20) | 121.21 | Buy |
| Williams %R (14) | -7.77 | Info |
| MACD (12,26,9) | 0.22 | Buy |
| ROC (12) | 7.38 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 92.23 | Sell |
| TRIX (15) | 0.33 | Buy |
| Awesome (5,34) | 2.34 | Buy |
| Ultimate (7,14,28) | 55.58 | Neutral |
| Momentum (10) | 2.84 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 42.04 | Sell |
| ADX (14) | 14.25 | Neutral |
| ATR (14) | 0.96 | Info |
Technical picture for the last 30 days shows a bullish tilt overall. The RSI14 is 60, with the 50-day simple moving average at $37.14 and the 200-day simple moving average at $30.45, suggesting upside momentum relative to key moving averages. Support is noted at $34.37 and resistance at $40.39, with a 30-day range from $33.71 to $48.40.
Annualized volatility is 50%, indicating notable price variability within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.55 | $41.75 | $55.35 | 0% | Neutral | |
| $42.61 | $53.45 | $70.92 | +28% | Bullish | |
| $44.99 | $58.02 | $79.84 | +39% | Bullish | |
| $49.18 | $64.88 | $91.89 | +55% | Bullish | |
| $61.73 | $83.10 | $120.56 | +99% | Bullish | |
| $74.07 | $101.56 | $150.47 | +143% | Bullish | |
| $86.88 | $121.18 | $182.96 | +190% | Bullish | |
| $94.04 | $133.29 | $204.71 | +219% | Bullish | |
| $94.29 | $135.69 | $211.71 | +225% | Bullish | |
| $107.93 | $157.60 | $249.50 | +277% | Bullish | |
| $169.68 | $264.65 | $445.43 | +534% | Bullish | |
| $313.03 | $546.87 | $1,006.36 | +12.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $25.55 | $41.75 | $49.08 | +0.00% |
| August 2026 | $35.35 | $41.69 | $50.48 | -0.14% |
| September 2026 | $35.77 | $42.48 | $52.01 | +1.89% |
| October 2026 | $35.07 | $41.90 | $51.78 | -1.36% |
| November 2026 | $35.02 | $42.06 | $52.38 | +0.37% |
| December 2026 | $36.57 | $44.13 | $55.35 | +4.92% |
Click any year to see its month-by-month RAPP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RAPP could reach as high as $55.35, with a base case around $41.75 and support toward $25.55 — roughly 0% from $41.75. Price action looks broadly range-bound.
Expect RAPP to range from $42.61 to $70.92 through 2027. The $53.45 average target implies a +28% move from current prices. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The RAPP price prediction for 2028 points to an average of $58.02 (low $44.99, high $79.84) — a potential gain of +39% on today's $41.75. Momentum favours further upside here.
In 2029, RAPP is projected to trade between $49.18 and $91.89, averaging $64.88 — a potential gain of +55% from today's $41.75. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Rapport Therapeutics, Inc.'s 2030 outlook centres on $83.10, within a $61.73 to $120.56 range. That is up +28% on the projected 2029 average. That marks a +99% change versus current levels. Momentum favours further upside here.
By 2031, RAPP could reach as high as $150.47, with a base case around $101.56 and support toward $74.07 — roughly +143% from $41.75. Buyers look set to stay in control over this stretch.
Expect RAPP to range from $86.88 to $182.96 through 2032. The $121.18 average target implies a +190% move from current prices. That is up +19% on the projected 2031 average. Momentum favours further upside here.
The RAPP price prediction for 2033 points to an average of $133.29 (low $94.04, high $204.71) — a potential gain of +219% on today's $41.75. Buyers look set to stay in control over this stretch.
In 2034, RAPP is projected to trade between $94.29 and $211.71, averaging $135.69 — a potential gain of +225% from today's $41.75. That is up +2% on the projected 2033 average. Momentum favours further upside here.
Rapport Therapeutics, Inc.'s 2035 outlook centres on $157.60, within a $107.93 to $249.50 range. That is up +16% on the projected 2034 average. That marks a +277% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RAPP could reach as high as $445.43, with a base case around $264.65 and support toward $169.68 — roughly +534% from $41.75. Momentum favours further upside here.
Expect RAPP to range from $313.03 to $1,006.36 through 2050. The $546.87 average target implies a +12.1x move from current prices. That is up +107% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RAPP today (≈ 23.952096 RAPP) could be worth
$13,098.63
+$12,098.63 (+1210%) by 2050 · US Dollar
Based on the average projected RAPP price of $546.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RAPPwould be worth at today's price.
$1,000 invested in RAPP on Jul 10, 2025 (≈ 65.019505 RAPP) would be worth
$2,714.56
+$1,714.56 (+171.5%) today · 2.71× · US Dollar
Based on a RAPP entry price of $15.38 vs. today's $41.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $38.97 | $1,071.34 | +7.1% |
| 1 month ago | $35.21 | $1,185.74 | +18.6% |
| 3 months ago | $34.17 | $1,221.83 | +22.2% |
| 6 months ago | $27 | $1,546.3 | +54.6% |
| 1 year ago | $15.38 | $2,714.56 | +171.5% |
| All time (2.1y) ago | $20.8 | $2,007.21 | +100.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RAPP forecast.
Our base-case forecast reaches $84.00 around 2031.
Implied market cap at $84.00: $4.02B
The multi-year forecast projects rising activity and higher price targets beyond 2026. The 2026 average is $40.39 with a 0% ROI and neutral sentiment. As we progress, the model shows bullish sentiment with the following year-by-year trajectory: 2027 avg $50.40, 2028 avg $55.21, 2029 avg $61.15, 2030 avg $76.67 (min $56.74, max $111.70) with ROI 89.8; 2031 avg $94.88, 2032 avg $111.39, 2033 avg $120.65, 2034 avg $124.93, 2035 avg $143.00.
Looking further ahead, 2040 offers an avg of $235.61 (min $150.06, max $398.82) with ROI 483.3, and 2050 shows an avg of $482.70 (min $273.72, max $894.15) with ROI 1095.1. Across these milestones, the forecast remains bullish, but these figures are estimates and not guarantees, subject to market and scientific outcomes.
Tap a question to reveal the answer.
In 2030, the forecast shows min $56.74, avg $76.67, max $111.70; ROI 89.8; sentiment BULLISH.
The forecast points to rising averages beyond 2026, with 2027 avg $50.40, 2040 avg $235.61, and 2050 avg $482.70; ROI figures of 24.8% (2027), 483.3% (2040), and 1095.1% (2050) accompany bullish sentiment, noting these are estimates and not guarantees.
The 2030 max is $111.70, while the 2031 max is $141.21, indicating that values above $120 could occur in later years according to the forecast (2031 and beyond) with bullish sentiment.
Current price is $40.39 and market cap is $1.93B; the rank is 1974.
The 2040 forecast shows min $150.06, avg $235.61, max $398.82 with ROI 483.3 and a bullish sentiment.
Rapport Therapeutics, Inc. Community Discussion
0Share your Rapport Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.